Phaseline

Companies › Hexun Biosciences

Hexun Biosciences: clinical trials, targets and expected readouts

1 active drug program in 1 registered trial: 1 Phase 1; Cardiovascular; next expected readout Dec 2028.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
HeXell-2020
allogeneic umbilical cord mesenchymal stem cells (UCMSCs)
–Phase 1Coronary Artery DiseaseDec 2028

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT07137104HeXell-2020Phase 1Coronary Artery DiseaseCardiovascularDec 2028

Targets

No annotated target.

Companies with the same targets

–

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.